AI Terminal
Aladdin Healthcare Technologies SE
Regulatory Filings • Oct 8, 2020
23_rns_2020-10-08_de021dc5-fcc9-4fee-a1d8-e47fb86b0881.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 8 October 2020 08:09
Aladdin Healthcare Technologies completes AI-driven Drug Discovery Platform (AIDD) for Commercial Use in Drug Development
DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Product Launch
08.10.2020 / 08:09
The issuer is solely responsible for the content of this announcement.
Aladdin Healthcare Technologies completes AI-driven Drug Discovery Platform (AIDD) for Commercial Use in Drug Development
– Aladdin has successfully released its proprietary AI Drug Discovery Platform to accelerate the drug development process.
– The automated machine learning platform pipeline covers main stages of early drug discovery: Virtual Screening, Hit to Lead known also as Lead Generation, Lead Optimisation and Preclinical Phase.
– With its proprietary platform, Aladdin has already identified and optimised multiple small molecule drug compounds with high potential for age-related diseases, including Alzheimer’s disease, Parkinson’s disease and SARS-CoV-2.
BERLIN/LONDON, October 8, 2020 – Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2 ), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has just successfully released its proprietary AI-driven Drug Discovery Platform.
Aladdin’s AI platform, by means of its groundbreaking components, such as ligand- and structure-based drug design using Artificial Intelligence (AI), can significantly speed up the process of drug development and even optimise new drug compounds. It generally takes 10 years to fully develop a new drug with a preclinical phase of 3 to 6 years. Thanks to Aladdin’s AI platform, the preclinical phase can be reduced to half.
The platform can also help in the process of designing and generating new drug-like molecules based on the target structure or small molecule ligands. Aladdin’s platform is therefore a relevant instrument for pharmaceutical companies, which can generate new compounds with annotated properties, such as ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity of the drug candidate), binding affinity and metabolic stability. In fact, the AIDD Platform acts like a big dynamic database, continuously kept updated with new data provided by Aladdin’s partners and customers. In this way, the innovative Big Data technology connects findings and dynamizes the knowledge progress for the treatment of diseases.
Wade Menpes-Smith, CEO of Aladdin healthcare Technologies, comments: “Aladdin can now officially provide valuable solutions to the pharmaceutical industry via our proprietary AI Drug Discovery Platform that can accelerate the drug development process, covering the process of Virtual Screening, Hit to Lead and Lead Optimisation.”
Aladdin is also working on several promising pipelines for the small molecule drug discovery in the early stage. Small molecule drugs are relatively simple chemical compounds. These compounds have a small molecular mass and their biggest advantage is the oral bioavailability. Already in May this year, Aladdin achieved two milestones in drug development against age-related diseases and COVID-19, by discovering new optimised compounds with its AIDD platform. The successful release of Aladdin’s proprietary platform confirms again the capability of the Company to achieve groundbreaking milestones in the field of drug development. This opens the door to many relevant partnerships in the pharmaceutical industry.
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.
Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI
For further information:
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: [email protected]
Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: [email protected]
08.10.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Aladdin Healthcare Technologies SE |
| Unter den Linden 10 | |
| 10117 Berlin | |
| Germany | |
| Phone: | 030 700140449 |
| E-mail: | [email protected] |
| Internet: | www.aladdinid.com |
| ISIN: | DE000A12ULL2 |
| WKN: | A12ULL |
| Listed: | Regulated Market in Dusseldorf |
| EQS News ID: | 1139561 |
| End of News | DGAP News Service |